Detection of Complement-fixing Antiphospholipid Antibodies in Association with Thrombosis

Summary

Antiphospholipid antibody (aPL) is a hallmark of antiphospholipid syndrome (APS), characterized by thrombosis and recurrent fetal loss. We developed a novel ELISA system to detect complement-fixing ability of anticardiolipin antibody (aCL), and evaluated its clinical usefulness through studying the prevalence of the antibodies in rheumatic diseases, especially in association with thrombosis and recurrent abortion. Among 189 patients with rheumatic diseases, the complement-fixing aCL was positive in 26 (83.9%) of 31 patients with APS and 2 (1.3%) of 158 with other disease categories, whereas it was not positive among 52 normal subjects. Twenty-seven of 28 patients (96.4%), who were positive for complement-fixing aCL, had the episodes or history of thrombosis and/or recurrent abortion, at the time we studied. The remaining one in this group developed APS manifesting pulmonary infarction and occlusion of mesenteric artery 6 months after the evaluation. The sensitivity and specificity of this assay system were 75.0% and 99.3%, respectively, in relation with thrombotic episodes. On the other hand, the IgG aCL were positive in 28 (77.8%) of 36 cases with recent thrombotic episodes and 24 (15.7%) of 153 cases with no recent thrombotic episodes. The sensitivity and specificity of IgG aCL assay system were 77.8% and 84.3%, respectively, in relation with thrombotic episodes. These results indicate that complement-fixing aCL may specifically occur in association with the episodes of thrombosis and/or recurrent abortion in patients with APS compared to IgG-aCL. The method for detecting the complement-fixing aCL is simple, and it provides the useful diagnostic marker for thrombotic manifestations associated with APS.

Keywords

Antiphospholipid antibodies - cardiolipin - complement - thrombosis - ELISA

• References

• 1 Hughes GRV. Thrombosis, abortion, cerebral disease, and the lupus antigoagulant. Br Med J 1983; 287: 1088-9.
• 2 Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-9.
• 3 Meroni PL, Del Papa N, Raschi E, Panzeri P, Borghi MO, Tincani A, Balestrieri G, Khamashta MA, Hughes GR, Koike T, Kritis SA. β2-glycoprotein I as a cofactor for anti-phospholipid reactivity with endothelial cells. Lupus 1998; 07 (Suppl. 02) S44-7.
• 4 Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211-9.
• 5 Carbone J, Orera M, Rodriguez-Mahou M, Rodriguez-Perez C, Sanchez-Ramon S, Seoane E, Rodriguez JJ, Zabay JM, Fernandez-Cruz E. Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss. Lupus 1999; 08: 274-8.
• 6 Tojo T, Friou GJ. Lupus nephritis: varying complement-fixing properties of immunoglobulin and antibodies to antigens of cell nuclei. Science 1968; 161: 904-6.
• 7 Platt JL. Mechanism of tissue injury in hyperacute xenograft rejection. ASAIO J 1992; 38: 8-16.
• 8 Bach FH, Robson SC, Ferran C, Winkler H, Millan MT, Stuhlmeier KM, Vanhove B, Blakely ML, van der Werf WJ, Hofer E. Endothelial cell activation and thromboregulation during xenograft rejection. Immunol Rev 1994; 141: 5-30.
• 9 Robson SC, Candinas D, Hancock WW, Wrighton C, Winkler H, Bach FH. Role of endothelial cells transplantation. Int Arch Allergy Immunol 1995; 106: 305-22.
• 10 Harris EN, Hughes GRV. Arthritis and Allied Conditions. In: Antiphospholipid antibodies. McCarty DJ, Koopman WJ. eds. Philadelphia: Lea and Febiger; 1989: 1068-79.
• 11 Tan EM, Cohen AS, Fries JF, Masti AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Vinchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
• 12 Seino J, Kinoshita Y, Sudo K, Horigome I, Sato H, Narita M, Noshiro H, Kudo K, Fukuda K, Saito T. Quantitation of C4 nephritic factor by an enzyme-linked immunosorbent assay. J Immunol Meth 1990; 128: 101-8.
• 13 Seino J, vd Wall Bake WI, van Es LA, Daha MR. A novel ELISA assay for the detection of C3 nephritis factor. J Immunol Meth 1993; 159: 221-7.
• 14 Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anticardiolipin antibody test: Report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215-22.
• 15 Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-8.
• 16 Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89: 1558-63.
• 17 Sthoeger ZM, Mozes E, Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Natl Acad Sci USA 1993; 90: 6464-7.
• 18 Amengual O. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276.
• 19 Simantov R. Activation of cultured vascular endothelial cells by anti-phospholipid antibodies. J Cliln Invest 1995; 96: 2211.
• 20 Atsumi T. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathgenic role for endothelin 1. Arthritis Rheum 1998; 41: 800.
• 21 Siegert CE, Daha MR, Tseng CM, Coremans IE, van Es LA, Breedveld FC. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993; 52: 851-6.
• 22 Uwatoko S, Mannik M, Oppliger IR, Okawa-Takatsuji M, Aotsuka S, Yokohari R, Seki G, Taniguchi S, Suzuki K, Kurokawa K. C1q-binding immunoglobulin G in MRL/l mice consists of immune complexes containing antibodies to DNA. Clin Immunol Immunopathol 1995; 75: 140-6.